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Diamond-Blackfan anemia (DBA) is congenital pure red-cell anemia due to a diﬀerentiation block in erythroid precursors. The
disease is commonly caused by mutations in genes for ribosomal proteins. Despite the identiﬁcation of disease causal genes, the
disease pathogenesis is not completely elucidated. The ribosomal abnormalities are assumed to inhibit globin translation which
may lead to excess free heme, stimulating a generation of free radicals and thereby damaging the precursors. We studied the
eﬀect of hemin (heme chloride) on cultured human erythroid precursors and found that contrary to aforementioned hypothesis,
although hemin moderately stimulated free radicals, it did not cause apoptosis or necrosis. In erythroid precursors derived from
DBA patients, hemin signiﬁcantly stimulated growth and hemoglobinization. Thus, heme toxicity is unlikely to play a role in the
pathophysiology of most DBA cases. Moreover, its beneﬁcial eﬀect in culture suggests a therapeutic potential.
1.Introduction
DBA is a rare congenital form of pure red-cell anemia,
characterized by macrocytic anemia, reticulocytopenia, and
a block in erythroid diﬀerentiation at the proerythroblast
stage, often in association with physical anomalies and
growth retardation [1]. A large proportion of the patients
carry mutations in genes encoding for ribosomal proteins,
for example, RPS19, RPS24, and RPS17 [1]. Based on
this genetic information, defects in ribosomal biogenesis
are postulated to underlie the pathogenesis of the disease
[1]. Although gross defects in ribosomal function are not
compatible with viability, subtle defects may exhibit tissue
speciﬁcity and impair only certain cellular functions where
the requirement for high-level translation for a particular
critical gene product is not fulﬁlled. In DBA, defects in
ribosomalbiogenesisaresuspectedtoimpairtheinitiationof
globin translation, causing a mismatch between intracellular
levels of globin chains and heme, a balance tightly coordi-
nated under normal conditions. It has been suggested that a
transient excess of heme is toxic to erythroid precursors via
iron-mediated generation of free radicals [2].
Heme, however, is not invariably toxic to developing
erythroid precursors (or to other cells) [3]. Exogenously
supplied hemin (heme chloride) is readily taken up by
cultured erythroid cells [4], and its iron is incorporated into
hemoglobin (Hb) or stored in ferritin [5]. Following the
addition of succinylacetone, a potent inhibitor of heme syn-
thesis, exogenously supplied hemin was shown to substitute
for intracellularly synthesized heme and to incorporate into
de novo formed Hb [5] .S e v e r a lg r o u p sr e p o r t e dt h a th e m i n
supplementation to semisolid cultures promotes the growth
of normal erythroid precursors, (e.g., [6]). We previously
showed, in a two-phase liquid culture, that hemin promotes
normal erythropoiesis by accelerating the proliferation and
hemoglobinization of erythroid precursors in the presence
[7]o ra b s e n c e[ 8] of holotransferrin. This eﬀect was
particularlyprominentduringtheearlystagesofmaturation,
when iron-uptake and heme synthesis are the rate-limiting
steps of hemoglobinization.
We now report that although hemin at subtoxic con-
centrations moderately stimulates free radical generation in
erythroid precursors, it does not cause apoptosis or necrosis.
In DBA erythroid precursors, hemin partially restores the2 Anemia
growth and diﬀerentiation potential. The beneﬁcial eﬀect
of hemin on these precursors may be related to its ability
to supply heme at early stages of hemoglobinization, when
heme synthesis is low, and thus overcome (at least partly) the
inhibitory eﬀect of their abnormal ribosomes. This suggests
that, contrary to what has previously been suggested [2],
heme excess does not play a role in the pathogenesis of most
cases of DBA. Furthermore, our data suggest that hemin
mightbeoftherapeuticpotentialinDBAandotherdisorders
with hematopoietic abnormalities associated with ribosomal
dysfunction.
2. Patientsand Methods
The research was approved by the Hadassah—Hebrew
University Medical Centre Human Experimentation Review
Board. Peripheral blood samples were obtained from normal
donors and patients that met the criteria of DBA [9].
Erythroid cells were cultured according to the two-phase
liquid culture procedure as previously described [10]. In
short, peripheral blood-derived mononuclear cells were ﬁrst
cultured in alpha medium supplemented with 10% fetal calf
serumand10%conditionedmediumobtainedfromcultures
of human bladder carcinoma cell line 5637 and 1μg/mL
cyclosporin A (phase I). After 6 days, nonadherent cells
were harvested, washed, and suspended in phase II medium,
containing alpha medium, 30% fetal calf serum, 1% bovine
serum albumin, 10μM β-mercaptoethanol, 1.5mM glu-
tamine, 10μM dexamethasone, 5ng/mL stem cell factor,
and 1U/mL human recombinant erythropoietin. Hemin
(bovine, Sigma, St. Louis, MO) was prepared as previously
described [7]. Intracellular Hb was quantiﬁed by HPLC as
previously described [7]. Hemogbloin-containing cells were
scored microscopically following staining with benzidine
dihydrochloride [10].
Reactive oxygen species (ROS), apoptosis, and necrosis
were measured by staining with 2 -7 -dichloroﬂuorescin
diacetate (DCF, Sigma), annexin-V, and propidium iodide,
and the cells were analyzed by ﬂow cytometry as previously
described [11].
3. Results andDiscussion
To study the potential toxic eﬀect of hemin on devel-
oping erythroid precursors, normal erythroid precursors
were cultured according to the two-phase liquid culture
procedure [10]. After 6 days in phase II culture, hemin (10–
50μM) was added for 16hrs. The cells were then harvested
and stained with DCF—a marker of free oxygen species
(ROS), phycoerythrin-conjugated annexin-V—a marker of
apoptosis which binds to phosphatidylserine exposed on the
outer surface of the cells or propidium iodide—a marker of
necrosis. The ﬂow cytometry results (Figure 1) indicate that
althoughROSgenerationwasmodestlystimulated,itwasnot
associated with apoptosis or necrosis.
We next studied the eﬀect of hemin in cultures of
erythroid cells derived from patients with DBA. Hemin was
added on the ﬁrst day of phase II. The cells were then
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Figure 1: Eﬀect of hemin on free radical generation, apoptosis, and
necrosis of erythroid precursors. Mononuclear cells derived from
the peripheral blood of normal donors were cultured according
to the two-phase liquid culture procedure. After 6 days in phase
II, hemin was added at the indicated concentrations for 16hrs.
Cells were harvested and stained with dichloroﬂuorescein diacetate,
phycoerythrin-conjugated Annexin-V, or propidium iodide and
analyzed by ﬂow cytometry. The reactive oxygen species (ROS)
data are presented as the mean ﬂuorescence channel; apoptosis
and necrosis data are presented as the percentage of positive cells.
The results (average ± SD N = 4) show a modest dose-dependent
stimulation of ROS by hemin but no eﬀect on apoptosis and
necrosis.
harvested on day 12. Hb-containing cells were enumerated
by benzidine staining (Figure 2(a)) and their Hb content,
by HPLC analysis (Figure 2(b)). In agreement with previous
reports in semisolid cultures [12], very poor growth of DBA
erythroid cells was observed in our liquid cultures. Hemin
(10–50μM) signiﬁcantly (4–20-fold, P < 0.001, and N =
6) increased their growth and hemoglobinization. Similar
results were obtained when hemin was added as heme
arginate (Leiras, Turku, Finland) (not shown).
Heme is involved in many metabolic pathways, including
regulation of transcription through inhibition DNA-binding
of the repressor, Bach1 [13]. In erythroid cells, it enhances
globin translation through inhibition of the activity (sub-
strate phosphorylation) of the repressor erythroid-speciﬁc
“eukaryoticinitiationfactor2αkinase”(eIF2αkinase)[14],it
accelerates globin mRNA synthesis [15], and it stabilizes the
newly synthesized globin chains by forming the Hb tetramer
[16]. Normally, intracellular heme concentration is tightly
controlled during erythroid diﬀerentiation: its synthesis is
regulated by modulation of iron uptake through surface
transferrin receptor-1 and the inducible 5-aminolevulinate
synthase, the ﬁrst enzyme of the heme synthetic pathway
[17]. Moreover, heme excess is evaded by its degradation
by heme oxygenase-1 [18] and its excretion by the heme
export pump (Flvcr) [4]. Mice carrying a mutation in this
pump present with a phenotype similar to human DBA [2].Anemia 3
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Figure 2: Eﬀect of hemin on development of erythroid precursors derived from patients with Diamond-Blackfan Anemia. Peripheral blood
mononuclear cells derived from 6 patients were cultured as in Figure 1. Hemin was added at the indicated concentrations on the ﬁrst day of
phase II. On day 12, hemoglobin-containing cells were enumerated microscopically following benzidine staining (a) and their intracellular
hemoglobin content, by HPLC (b). The data represent the mean of duplicate cultures of cells derived from each patient. The results show
signiﬁcant (P < 0.001) stimulation by hemin of erythroid cell growth and hemoglobinization.
The phenotypic similarity between the mouse model and the
human disease led to hypothesis that heme excess may play
a central role in the pathogenesis of DBA although no defect
in this pump is found in patients [19].
Our data show that in vitro hemin within a particular
concentration range is nontoxic to erythroid precursors,
and, importantly, in DBA-derived cultures, it stimulates
growth and hemoglobinization. These ﬁndings rule out
the possibility that defective erythropoiesis in DBA is a
consequence of intracellular accumulation of excess of heme.
The beneﬁcial eﬀect of exogenous hemin on developing
DBA erythroid precursors could be related to its ability to
supply heme when heme synthesis is low and thus accelerate
globin and Hb accumulation. This might overcome (at least
partially) the inhibitory eﬀect of their abnormal ribosomes,
suggesting that hemin may be of therapeutic potential in
DBA and other disorders with hematopoietic abnormalities
associated with ribosomal dysfunction.
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